MiMedx Group Past Earnings Performance
Past criteria checks 5/6
MiMedx Group has been growing earnings at an average annual rate of 57.6%, while the Biotechs industry saw earnings growing at 24.8% annually. Revenues have been growing at an average rate of 3.6% per year. MiMedx Group's return on equity is 47.4%, and it has net margins of 23.2%.
Key information
57.6%
Earnings growth rate
56.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 3.6% |
| Return on equity | 47.4% |
| Net Margin | 23.2% |
| Next Earnings Update | 26 Feb 2025 |
Recent past performance updates
Recent updates
We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease
Dec 23
We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease
Nov 21There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise
Nov 06MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry
May 21We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
May 14Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet
Mar 27We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
Jan 05MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Dec 18Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?
Aug 08Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?
Apr 22Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?
Dec 20MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX
Sep 12MiMedx Group expects AWC full-year sales in low end of 11%-14% growth range
Sep 06Revenue & Expenses Breakdown
How MiMedx Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 343 | 79 | 210 | 11 |
| 30 Jun 24 | 340 | 79 | 209 | 11 |
| 31 Mar 24 | 335 | 68 | 216 | 12 |
| 31 Dec 23 | 321 | 56 | 216 | 13 |
| 30 Sep 23 | 309 | 19 | 215 | 6 |
| 30 Jun 23 | 295 | 2 | 219 | 8 |
| 31 Mar 23 | 281 | -18 | 225 | 10 |
| 31 Dec 22 | 268 | -27 | 221 | 13 |
| 30 Sep 22 | 261 | -34 | 216 | 22 |
| 30 Jun 22 | 256 | -28 | 209 | 20 |
| 31 Mar 22 | 258 | -19 | 202 | 19 |
| 31 Dec 21 | 242 | -18 | 199 | 10 |
| 30 Sep 21 | 260 | -35 | 223 | 16 |
| 30 Jun 21 | 261 | -83 | 233 | 15 |
| 31 Mar 21 | 246 | -88 | 231 | 13 |
| 31 Dec 20 | 248 | -83 | 240 | 12 |
| 30 Sep 20 | 256 | -73 | 212 | 11 |
| 30 Jun 20 | 281 | -8 | 210 | 10 |
| 31 Mar 20 | 294 | -17 | 233 | 11 |
| 31 Dec 19 | 299 | -26 | 265 | 11 |
| 30 Sep 19 | 315 | -54 | 270 | 13 |
| 30 Jun 19 | 314 | -67 | 287 | 14 |
| 31 Mar 19 | 342 | -48 | 295 | 15 |
| 31 Dec 18 | 359 | -30 | 295 | 16 |
| 30 Sep 18 | 354 | 41 | 275 | 15 |
| 30 Jun 18 | 352 | 59 | 260 | 16 |
| 31 Mar 18 | 333 | 65 | 235 | 17 |
| 31 Dec 17 | 321 | 65 | 220 | 18 |
| 30 Sep 17 | 303 | 35 | 216 | 18 |
| 30 Jun 17 | 283 | 21 | 205 | 15 |
| 31 Mar 17 | 264 | 15 | 192 | 14 |
| 31 Dec 16 | 222 | 0 | 172 | 14 |
| 30 Sep 16 | 227 | 20 | 168 | 11 |
| 30 Jun 16 | 212 | 23 | 154 | 10 |
| 31 Mar 16 | 200 | 27 | 144 | 9 |
| 31 Dec 15 | 187 | 29 | 133 | 8 |
| 30 Sep 15 | 175 | 20 | 126 | 8 |
| 30 Jun 15 | 160 | 17 | 115 | 8 |
| 31 Mar 15 | 139 | 11 | 104 | 7 |
| 31 Dec 14 | 118 | 6 | 90 | 7 |
| 30 Sep 14 | 97 | 1 | 75 | 7 |
| 30 Jun 14 | 79 | -3 | 64 | 6 |
| 31 Mar 14 | 67 | -3 | 54 | 5 |
Quality Earnings: MDXG has a high level of non-cash earnings.
Growing Profit Margin: MDXG's current net profit margins (23.2%) are higher than last year (6.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MDXG has become profitable over the past 5 years, growing earnings by 57.6% per year.
Accelerating Growth: MDXG's earnings growth over the past year (315.6%) exceeds its 5-year average (57.6% per year).
Earnings vs Industry: MDXG earnings growth over the past year (315.6%) exceeded the Biotechs industry 36.7%.
Return on Equity
High ROE: MDXG's Return on Equity (47.4%) is considered outstanding.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 03:09 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MiMedx Group, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Wittes | Brean Capital |
| William Plovanic | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |